Resveratrol synergizes with cisplatin to suppress osteosarcoma U2-OS cells via up-regulating Cx43 and inducing ROS-dependent apoptosis
Hong-Bo Xing, Hao-Yu Li, Gui-Zhou Zheng, Qi-Hao Zhang, Lei Zhai, Xiang Wu, Shi-Xin Du, Xue-Dong Li · 2025
Read Resveratrol synergizes with cisplatin to suppress osteosarcoma U2-OS cells via up-regulating Cx43 and inducing ROS-dependent apoptosis by Hong-Bo Xing, Hao-Yu Li, Gui-Zhou Zheng, Qi-Hao Zhang, Lei Zhai, Xiang Wu, Shi-Xin Du, Xue-Dong Li (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12728134.txt.
Description
Hong-Bo Xing leads a team in a 2025 study of resveratrol joined with cisplatin against osteosarcoma cells. Resveratrol, a compound from plants, is known to boost the punch of many cancer drugs. Whether it lifts cisplatin against this bone cancer, and how, was not known.
The team dosed a human osteosarcoma cell line with each drug alone and with both at once. Growth, cell death, movement, and invasion were each measured, and a key signaling path was read. The pair beat either drug alone, the tests show. The effect runs through a gap-junction protein and a burst of reactive oxygen that pushes the cells to die.
Catalog record
| CREATOR | Hong-Bo Xing, Hao-Yu Li, Gui-Zhou Zheng, Qi-Hao Zhang, Lei Zhai, Xiang Wu, Shi-Xin Du, Xue-Dong Li |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |